Identification of an optimal absolute lymphocyte count at leukapheresis in patients with lymphoma treated with CART

Blood Immunology & Cellular Therapy 2026 Open access

Read full text
Authors: Kunhwa Kim, Zachary E. Hunzeker, Xiaowen Sun, Ryan Sun, Timothy J. Voorhees, Youssef Youssef, Narendranath Epperla, Michelly De Castro, Karla Ow, Minifrida Santiago, Jaimole Varghese, Amy A. Ayers
+10 more Jeremy Ramdial, Chitra M. Hosing, Partow Kebriaei, Elizabeth J. Shpall, Michael D. Jain, Julio Chavez, Frederick Lundry Locke, Sattva Swarup Neelapu, Sairah Ahmed, Paolo Strati
DOI: 10.1016/j.bict.2026.100042
Cited by: 0
References: 24

Abstract

/μL at the time of apheresis is associated with optimal outcomes in patients with LBCL treated with axi-cel. A deeper investigation of the impact of prior therapies on the number and phenotype of lymphocytes at time of apheresis is warranted.

Fields of Study & Subjects

CAR-T cell therapy research Lymphoma Diagnosis and Treatment T-cell and B-cell Immunology

Publication details

Journal / source
Blood Immunology & Cellular Therapy
Volume
2
Issue
2
Pages
100042–100042
Publication date
5 March 2026
Language
EN